histori
veterinari
vaccin
develop
start
wellknown
stori
loui
pasteur
rabbit
spinal
cord
vaccin
continu
day
demonstr
protect
anim
rabi
viru
revers
transcriptas
dna
plasmid
frenkel
use
suspens
epithelium
obtain
tongu
recent
slaughter
healthi
cattl
maintain
vitro
subsequ
infect
manner
similar
use
today
babi
hamster
kidney
cell
produc
foot
mouth
diseas
viru
fmdv
frenkel
procedur
becam
corner
stone
vaccin
product
mani
year
pave
way
modern
biotechnolog
know
recent
recombin
pox
virus
gener
vaccin
heterolog
pathogen
use
vacciniavector
express
rabi
viru
glycoprotein
newcastl
diseas
viru
fusion
hemagglutinin
ha
glycoprotein
first
applic
genet
engin
tradit
vaccin
involv
use
inactiv
liveattenu
subunit
vaccin
inactiv
kill
vaccin
consist
treat
microorgan
unabl
replic
howev
elicit
protein
product
cytosol
henc
viral
antigen
present
mhc
class
molecul
thu
cytotox
cell
gener
liveattenu
vaccin
gener
far
potent
educ
greater
number
relev
effector
mechan
includ
cytotox
cell
nevertheless
vaccin
sometim
residu
pathogen
viru
strain
may
reemerg
seri
subunit
vaccin
would
effect
live
whole
organ
inher
safer
vaccin
base
whole
organ
strongli
immunogen
particularli
difficult
obtain
mhc
class
specif
develop
vaccin
therefor
remain
import
goal
immunolog
moreov
remain
need
vaccin
reduc
econom
impact
diseas
product
anim
ideal
vaccin
efficaci
prevent
infect
although
total
unrealist
therefor
realist
vaccin
provid
greater
efficaci
diseas
prevent
within
day
coupl
week
singl
administr
furthermor
order
reduc
cost
regular
reimmun
ensur
receipt
complet
vaccin
schedul
protect
long
durat
use
minim
number
dose
addit
ideal
vaccin
would
also
stimul
mucos
immun
sinc
major
virus
enter
via
mucos
surfac
thu
perfect
vaccin
design
deliv
mucos
rout
intranas
oral
deliveri
prefer
vaccin
also
need
safe
caus
advers
side
reaction
immunosuppress
interfer
immun
vaccin
given
simultan
final
vaccin
need
genet
thermal
stabl
genet
stabil
must
present
ensur
absenc
revers
live
vaccin
virul
organ
might
caus
diseas
thermal
stabil
critic
sinc
mainten
cold
chain
alway
guarante
manufactur
deliveri
import
desir
characterist
vaccin
deliv
anim
young
age
stimul
immun
presenc
innat
passiv
anoth
import
criterion
ideal
vaccin
veterinari
medicin
low
cost
especi
import
develop
countri
poultri
vaccin
vaccin
must
sell
cent
dose
unfortun
ideal
vaccin
rare
veterinari
field
addit
still
sever
diseas
effect
vaccin
histori
heterolog
gene
express
adenoviru
ad
goe
back
discoveri
simian
viru
contamin
inactiv
ad
strain
vaccin
adapt
growth
rhesu
monkey
kidney
cell
observ
tantigen
occasion
incorpor
ad
genom
led
realiz
ad
could
use
express
heterolog
recognit
purifi
replicationdefect
ad
could
propag
cell
without
helper
virus
pave
way
toward
intent
product
genet
modifi
popular
ad
recombin
viral
vector
larg
due
success
safe
immun
million
us
militari
recruit
enter
coat
prevent
acut
respiratori
diseas
ard
follow
first
trial
number
recombin
ad
rad
recent
construct
test
human
also
veterinari
ad
highli
efficaci
vaccin
carrier
strong
immunogen
although
abil
ad
vector
elicit
antigenspecif
cell
well
describ
littl
known
kinet
natur
immun
respons
follow
ad
howev
yang
et
observ
ad
vector
abil
deliv
larg
amount
antigen
lymphoid
tissu
ii
abil
induc
rapid
expans
migrat
cell
throughout
lymphat
system
iii
abil
produc
sustain
highlevel
tcell
respons
may
explain
strong
immunogen
vector
use
rad
veterinari
vaccin
mani
advantag
infect
wide
varieti
divid
nondivid
cell
ii
ad
infect
ubiquit
normal
without
signific
sever
clinic
symptom
iii
administ
oral
iv
ad
genom
well
character
v
accommod
kb
foreign
genet
materi
vi
genom
rare
integr
host
chromosom
vii
techniqu
well
establish
construct
rad
vector
viii
abil
replic
high
titer
complement
cell
ad
nonenvelop
icosahedr
viru
nm
linear
duplex
dna
genom
kb
genom
divid
earli
e
late
l
gene
express
respect
replic
viral
chromosom
figur
gene
product
involv
control
viral
gene
transcript
shutoff
cellular
protein
cellular
transform
gene
code
protein
involv
viral
replic
includ
dnabind
protein
involv
dna
elong
dna
polymeras
gene
dispens
ad
replic
code
protein
interfer
host
immun
respons
viru
infect
final
gene
involv
transit
earli
late
gene
express
shutoff
hostcel
gene
express
viral
replic
assembl
virion
see
review
firstgener
vector
usual
delet
region
howev
product
perform
cell
recombin
left
terminu
firstgener
ad
vector
partial
overlap
sequenc
cellular
genom
may
result
gener
replicationcompet
ad
rca
seriou
safeti
concern
nonrepl
vector
desir
secondgener
vector
replicativedefect
ad
delet
show
reduc
immunogen
rca
gener
engin
stabl
cell
line
complement
vector
cumbersom
lead
poor
cell
growth
viral
rad
vector
develop
either
replicationcompet
express
cassett
foreign
antigen
place
gene
replicationdefect
virus
antigen
express
cassett
replac
despit
fact
would
prefer
work
replicationdefect
viru
differ
studi
support
use
rca
veterinari
vaccin
sinc
abil
replicationdefect
form
induc
mucos
immun
protect
respiratori
challeng
follow
immun
report
moreov
rcabas
vaccin
known
potenti
overrid
maternalderiv
addit
cattl
vaccin
rad
show
use
replicationdefect
form
induc
lower
titer
antibodi
replicationcompet
form
intratrachealsubcutan
current
human
rad
repres
one
effici
vector
system
deliveri
vaccin
antigen
howev
use
human
ad
vaccin
deliveri
system
nonhuman
anim
still
limit
sinc
nonhad
speci
specif
develop
animalspecif
ad
vaccin
deliveri
system
would
logic
choic
thu
ad
isol
speci
man
gener
increas
interest
particularli
canin
ad
cad
abil
replic
persist
local
upper
respiratori
tract
puppi
face
maternalderiv
antibodi
administ
via
intranas
rout
use
deped
independ
coxsackieviru
group
b
ad
receptor
car
pathay
enter
cell
avian
ad
subject
numer
investig
number
featur
make
attract
poultri
industri
eas
propag
eas
administr
water
aerosol
inject
larg
rang
serotyp
vari
virul
chicken
embryo
lethal
orphan
celo
classifi
type
fowl
ad
fad
studi
vector
viru
like
typic
avian
ad
much
larger
genom
mammalian
ad
despit
larg
scatter
never
associ
seriou
diseas
econom
loss
poultri
industri
isol
healthi
chicken
induc
clinic
sign
experiment
inocul
chicken
also
viru
use
depend
independ
car
pathway
enter
cell
porcin
ad
pad
depend
upon
serotyp
grown
pig
kidney
testi
retina
thyroid
cell
human
kidney
canin
melanoma
calf
kidney
cell
requir
adjuv
induct
proper
immun
respons
infect
gener
sub
clinic
caus
advers
effect
produc
pig
pad
also
isol
appar
healthi
pig
pad
speci
specif
isol
swine
reduc
possibl
spread
anim
man
follow
administr
pad
could
induc
system
mucos
antibodi
respons
andiv
bovin
ad
serotyp
like
pad
requir
adjuv
induct
proper
immun
respons
use
due
lack
virul
moreov
experiment
infect
calv
fail
produc
either
clinic
sign
gross
lesion
anim
seroconvert
cell
entri
pathway
well
infect
cat
felin
immunodefici
viru
fiv
result
immunosuppress
diseas
transmit
blood
saliva
fiv
invad
destroy
monocytemacrophag
system
infect
b
differ
approach
made
tri
immun
cat
fiv
far
effect
vaccin
made
gonin
et
year
ago
construct
replicationdefect
contain
envelop
protein
env
gene
fiv
howev
despit
fact
antibodi
respons
pseudorabi
viru
cat
show
potenti
vector
use
speci
cat
inject
tissu
cultur
infecti
dose
adjuv
montanid
isa
water
nonminer
oil
montanid
isa
doubl
waterminer
oilwat
rad
develop
detect
antibodi
respons
env
moreov
observ
even
high
titer
antibodi
env
product
induc
could
still
insuffici
sinc
work
appar
perform
concern
use
ad
vector
potenti
vaccin
fiv
canin
distemp
viru
cdv
induc
fatal
diseas
includ
enceph
demyelin
diarrhea
respiratori
disord
dog
although
convent
live
modifi
vaccin
commerci
avail
wide
use
field
efficaci
limit
presenc
matern
deriv
thu
new
improv
cdv
vaccin
could
overcom
limit
would
constitut
signific
improv
construct
character
first
replicationcompet
start
recent
gene
code
cdv
fusion
f
protein
insert
two
use
candid
vaccin
puppi
report
intranas
vaccin
mixtur
contain
provid
excel
level
protect
seroneg
puppi
induc
almost
complet
protect
contrast
intranas
immun
puppi
born
cdv
immun
dam
fail
activ
specif
protect
immun
respons
howev
puppi
vaccin
subcutan
signific
seroconvers
solid
protect
immun
trigger
furthermor
signific
prime
memori
respons
evidenc
immedi
challeng
constitut
effici
strategi
overcom
passiv
activ
adspecif
immun
dog
rabi
still
present
health
threat
human
also
dog
cat
dog
import
vector
human
especi
less
develop
nation
uncontrol
canin
rabi
often
endem
replicationcompet
defect
express
rabi
glycoprotein
rg
develop
induc
immun
rabi
rodent
canin
fox
skunk
given
intramuscular
subcutan
intranas
rout
dose
howev
oral
immun
fail
induc
measur
antibodi
respons
rabi
viru
rv
use
dog
previous
vaccin
commerci
avail
vaccin
immun
plaqu
form
unit
pfu
anim
replicationdefect
express
rg
develop
higher
titer
viral
neutral
antibodi
rv
day
vaccin
compar
convent
vaccin
similar
condit
moreov
immun
dog
commerci
nonad
vaccin
requir
yearli
best
everi
year
depend
type
vaccin
hand
higher
antibodi
titer
obtain
ad
vaccin
rv
would
reduc
frequenc
dog
immun
reduc
cost
pet
one
import
advantag
recombin
vaccin
fact
immun
respons
rg
shown
impair
matern
immun
thu
ad
vaccin
highli
suitabl
neonat
infecti
bronchiti
viru
ibv
highli
contagi
pathogen
poultri
caus
signific
morbid
mortal
depend
strain
ibv
target
respiratori
tract
kidney
oviduct
result
nephriti
reduc
egg
product
addit
ibv
serotyp
identifi
worldwid
new
serotyp
variant
identifi
result
widespread
use
live
attenu
vaccin
differ
approach
develop
order
gener
efficaci
vaccin
ibv
express
glycoprotein
involv
attach
cellular
receptor
vaccinia
viru
abl
induc
virusneutr
antibodi
ibv
deliv
mice
howev
multipl
inject
requir
achiev
reason
degre
protect
recent
fad
express
ibv
singl
dose
shown
suffici
obtain
complet
protect
chicken
trachea
primari
site
infect
ibv
moreov
even
face
fav
matern
antibodi
high
level
protect
infecti
bursal
diseas
viru
ibdv
induc
immunosuppress
diseas
chicken
destruct
b
lymphocyt
current
vaccin
altern
consist
either
live
viru
inactiv
oilemuls
vaccin
induc
serum
antibodi
product
breed
hen
natur
exposur
transfer
progeni
chick
via
yolk
sac
provid
protect
first
critic
week
construct
contain
gene
ibdv
recombin
vaccin
shown
induc
immun
respons
chicken
vaccin
pfuanim
moreov
challeng
ibdv
intraven
intraperiton
subcutan
intramuscularli
vaccin
chicken
protect
although
protect
observ
conjunctiv
sac
vaccin
classic
swine
fever
csf
also
known
hog
cholera
seriou
contagi
viral
diseas
pig
high
mortal
rate
difficult
control
area
high
pig
wild
boar
densiti
econom
import
diseas
swine
area
intens
pig
farm
reason
csf
includ
list
infecti
diseas
highest
import
intern
trade
thu
highli
relev
develop
efficaci
vaccin
control
csf
viru
csfv
domest
pig
wild
boar
prophylact
vaccin
still
carri
mani
part
new
vaccin
develop
includ
number
differ
strategi
deliv
major
envelop
glycoprotein
neutral
antibodi
hammond
et
construct
first
rpad
express
protein
show
singl
dose
tissu
cultur
supernat
administ
subcutan
suffici
complet
protect
pig
subcutan
challeng
later
author
show
challeng
administ
oral
anim
protect
recent
shown
pig
given
two
oral
dose
rpad
complet
protect
pseudorabi
viru
prv
alpha
herpesviru
caus
econom
import
widespread
aujeszki
diseas
ajd
pig
prv
highli
neurotrop
viru
caus
nervou
respiratori
complic
pig
natur
host
varieti
anim
speci
vaccin
ajd
wide
practis
live
attenu
kill
whole
viru
vaccin
howev
neonat
immun
often
limit
presenc
matern
deriv
antibodi
inhibit
immun
respons
recent
use
rad
vaccin
carri
individu
prv
gene
construct
safe
altern
glycoprotein
gd
gb
gc
prv
chosen
basi
role
elicit
protect
immun
respons
viru
infect
shown
piglet
vaccin
intramuscularli
day
birth
replicationcompet
harbour
three
gene
develop
similar
neutral
antibodi
respons
independ
presenc
absenc
matern
antibodi
partial
protect
challeng
week
pig
slaughter
month
birth
oneshot
vaccin
birth
could
provid
protect
suffici
durat
final
two
dose
ml
clarifi
tissu
cultur
supernat
contain
rpad
express
prv
gd
gene
administ
subcutan
show
protect
pig
challeng
postmorten
gross
lesion
pneumonia
found
lung
pig
given
singl
dose
vaccin
lung
pig
given
two
dose
free
foot
mouth
diseas
fmd
sever
clinic
acut
vesicular
diseas
clovenhoof
anim
includ
domest
rumin
pig
wildlif
speci
pig
recogn
signific
factor
spread
diseas
sinc
singl
pig
releas
much
aerosol
viru
cattl
short
period
econom
social
impact
fmd
catastroph
outbreak
occur
fmdfree
countri
popul
immunolog
naiv
anim
current
vaccin
chemic
inactiv
prepar
concentr
infect
cell
cultur
supernat
howev
fmdfree
countri
gener
prohibit
use
lack
approv
diagnost
test
reliabl
distinguish
vaccin
infect
anim
moreov
current
vaccin
induc
protect
respons
approxim
day
post
vaccin
critic
issu
diseasefre
countri
case
fmd
outbreak
rapid
control
prevent
spread
diseas
crucial
see
review
thu
need
develop
diseas
control
strategi
reli
rapidli
induc
protect
mayer
et
develop
replicationdefect
vector
contain
capsid
polypeptid
viral
proteas
code
region
necessari
process
capsid
protein
fmdv
strain
observ
vaccin
swine
pfuanim
pb
develop
antibodi
fmdv
structur
protein
fmdvspecif
neutral
antibodi
respons
seem
increas
slightli
boost
swine
second
inocul
pfuanim
pb
week
post
initi
vaccin
protocol
shown
offer
signific
degre
protect
pig
five
six
pig
complet
protect
remain
anim
significantli
reduc
sign
diseas
later
mora
et
show
singl
dose
pfuanim
pb
replicationdefect
express
code
region
fmdv
strain
complet
protect
pig
homolog
challeng
day
vaccin
sinc
efficaci
vaccin
strain
depend
infect
one
serotyp
confer
protect
anoth
bicistron
vector
vaccin
decreas
cost
multival
adenovir
fmd
vaccin
construct
vector
capsid
code
region
strain
proteas
code
region
strain
use
howev
neutral
antibodi
respons
vaccin
pfuanim
pb
bicistron
vector
consider
lower
induc
commerci
fmd
vaccin
monoval
recent
new
strategi
base
fact
fmdv
highli
sensit
alphabeta
interferon
develop
use
replicationdefect
strategi
shown
complet
protect
pig
vaccin
pfuanim
challeng
h
later
virul
fmdv
porcin
respiratori
reproduct
syndrom
viru
prrsv
caus
agent
econom
import
pig
diseas
worldwid
distribut
character
reproduct
failur
sow
respiratori
problem
unwean
grow
pig
swine
macrophag
cell
type
known
support
prrsv
replic
make
commerci
product
imposs
direct
contact
infect
naiv
pig
predomin
rout
prrsv
transmiss
moreov
pneumonia
caus
prrsv
infect
sever
young
pig
compar
adult
may
complic
concurr
bacteri
gonin
et
observ
prrsvinfect
pig
present
circul
antibodi
respons
viral
neutral
mainli
direct
envelop
protein
gagnon
et
construct
replicationdefect
express
protein
use
recombin
viru
immun
pig
use
two
intraderm
inject
pfuanim
mixtur
contain
pb
poloxam
observ
follow
challeng
given
intranas
day
booster
pig
produc
high
antibodi
titer
protein
moreov
vaccin
pig
present
specif
immun
memori
follow
subsequ
prrsv
infect
result
rapid
clonal
expans
memori
cell
neutral
epitop
authent
viral
protein
transmiss
gastroenter
corona
viru
tgev
infect
enter
respiratori
tissu
newborn
piglet
result
mortal
approach
viru
infect
epitheli
cell
case
lung
sever
commerci
avail
tgev
vaccin
inactiv
attenu
fulli
protect
piglet
sever
attempt
made
develop
efficaci
recombin
tgev
spike
protein
identifi
major
induc
tgevneutr
antibodi
mediat
bind
tgev
cellular
thu
express
protein
construct
use
studi
induct
antibodi
provid
protect
observ
porcin
serum
elicit
pfuanim
pb
recombin
mix
lethal
dose
viru
prior
administr
suscept
pig
prevent
replic
virul
tgev
administ
oral
mixtur
fulli
protect
swine
clinic
sign
death
moreov
use
dose
produc
clinic
symptom
anim
inocul
week
suggest
vector
use
live
vaccin
swine
without
secondari
complic
associ
vector
howev
pad
vector
could
effect
thu
tuboli
construct
express
tgev
protein
observ
singl
oral
dose
pfuanim
recombin
viru
suffici
induc
system
local
humor
immun
unfortun
challeng
experi
carri
swine
influenza
viru
siv
widespread
import
pathogen
speci
divers
poultri
swine
marin
mammal
human
pig
influenza
occur
either
enzoot
problem
herd
commonli
explos
outbreak
ard
although
rare
fatal
swine
influenza
substanti
econom
addit
grow
concern
potenti
synergist
infect
influenza
prrsv
beyond
impact
influenza
swine
industri
pig
also
import
global
ecolog
influenza
virus
siv
vaccin
commerci
avail
inactiv
wholeviru
subunit
vaccin
vaccin
may
decreas
incid
sever
clinic
diseas
consist
provid
complet
protect
viru
infect
two
replicationdefect
develop
potenti
vaccin
siv
express
influenza
viru
induc
predomin
subtypespecif
humur
immun
respons
express
nucleoprotein
np
groupspecif
stimul
cytotox
lymphocyt
crossreact
immun
influenza
observ
immun
mice
pig
pb
first
recombin
describ
develop
high
level
virusspecif
hemagglutinationinhibit
antibodi
siv
week
post
vaccin
anim
partial
protect
hand
pig
vaccin
pb
recombin
virus
mixtur
complet
protect
bovin
viral
diarrhea
viru
bvdv
respons
reduc
milk
product
reduc
reproduct
perform
growth
retard
addit
acut
infect
adult
cattl
congenit
defect
increas
neonat
mortal
also
clinic
manifest
bvdv
final
report
bvdv
may
play
indirect
role
current
inactiv
modifiedl
vaccin
use
howev
type
vaccin
signific
shortcom
express
nucleocapsid
c
protein
highli
conserv
among
mani
differ
pestivirus
bvdv
belong
construct
shown
induc
humor
cellular
immun
respons
vaccin
pfuanim
mous
protein
bvdv
major
viral
glycoprotein
also
use
mice
immun
use
vector
strong
humor
immun
respons
detect
presenc
strong
memori
respons
protein
strategi
use
inducerpromot
allow
gener
rad
product
transgen
may
toxic
permit
control
transgen
express
vitro
vivo
final
express
bvdv
protein
construct
shown
induc
bvdv
mucos
system
immun
respons
intranas
immun
pfuanim
cotton
despit
fact
mice
immun
recombin
fowl
pox
viru
dna
vaccin
express
glycoprotein
induc
immun
respons
also
observ
neutral
titer
bovin
parainfluenza
viru
type
isol
normal
cattl
cattl
show
sign
respiratori
diseas
abort
fetus
intramammari
inocul
result
respiratori
sign
fever
malais
moreov
milk
show
color
chang
increas
ph
increas
number
glandular
epitheli
cell
neutrophil
lymphocyt
current
multival
vaccin
contain
kill
use
brekerklassen
et
construct
two
encod
either
f
hn
protein
shown
intranas
vaccin
pfuanim
pb
cotton
rat
produc
strong
serolog
respons
within
day
increas
second
vaccin
moreov
f
hn
protein
produc
either
alon
combin
suffici
induc
protect
immun
bovin
herp
viru
caus
varieti
diseas
cattl
includ
infecti
bovin
rhinotrach
infecti
pustular
vulvovagin
conjunct
occasion
meningoenceph
live
attenu
kill
vaccin
partial
effect
reduc
diseas
incid
limit
exist
vaccin
encourag
develop
altern
costeffect
vaccin
strategi
recombin
live
viral
vectorbas
vaccin
mittal
et
develop
first
replicationcompet
defect
carri
gd
glycoprotein
gene
envelop
show
form
induc
immun
cotton
rat
vaccin
pfuanim
pb
infecti
virion
isol
trachea
rat
challeng
strategi
use
test
abil
induc
mucos
system
immun
respons
cotton
success
recent
newborn
lamb
immun
pfuanim
replicationdefect
express
gd
protein
humor
cellmedi
gdspecif
mucos
immun
respons
detect
lamb
singl
immun
respons
qualit
quantit
similar
detect
weekold
lamb
moreov
gdspecif
matern
antibodi
significantli
alter
either
mucos
system
gdspecif
immun
respons
addit
glycoprotein
gc
also
test
abil
induc
protect
immun
cattl
intranas
administr
pfuanim
use
replicationdefect
howev
observ
highest
neutral
antibodi
titer
obtain
express
gd
protein
follow
live
vaccin
high
mortal
high
morbid
rate
rinderpest
rp
pest
de
petit
rumin
ppr
dread
anim
diseas
draw
back
anim
product
mani
develop
countri
africa
asia
affect
domest
wild
rumin
belong
list
offic
intern
de
epizooti
highli
contagi
anim
diseas
high
econom
import
group
current
attenu
tissu
cultur
vaccin
use
control
rp
ppr
virus
success
use
mani
year
safe
effect
provid
complet
lifelong
protect
singl
subcutan
howev
vaccin
program
oral
rout
administr
would
econom
moreov
parenter
way
administr
mean
current
vaccin
use
wildlif
laboratori
product
purif
encapsul
process
replicationdefect
express
two
differ
morbilliviru
capsid
protein
respons
agent
diseas
progress
aim
develop
heat
stabl
rpppr
oral
vaccin
better
adapt
mass
vaccin
hot
climat
develop
countri
anim
vaccin
challeng
test
ongo
promis
preliminari
result
summari
accord
numer
report
studi
live
human
nonhuman
rad
either
infecti
appear
attract
candid
vaccin
sever
anim
diseas
tabl
success
situat
clear
pathogen
report
intermedi
success
appar
cdv
rp
viru
rpv
ppr
viru
pprv
wherea
vaccin
fiv
thu
far
yield
poor
inconclus
result
nevertheless
comprehens
pictur
sinc
viral
agent
veterinari
import
known
tabl
process
design
critic
develop
costeffect
veterinari
vaccin
goal
minim
number
process
step
prerequisit
industri
applic
intend
addit
veterinari
vaccin
impos
final
puriti
requir
human
vaccin
reflect
purif
scheme
product
ad
vaccin
veterinari
applic
mainli
base
upon
use
continu
cell
line
hela
cell
prolifer
step
variou
anim
sera
use
enhanc
cell
growth
howev
supplement
cell
cultur
media
compon
present
sever
drawback
like
lot
lot
variat
potenti
risk
contamin
virus
mycoplasma
prion
furthermor
regulatori
author
europ
european
medicin
agenc
emea
unit
state
food
drug
administr
fda
encourag
biolog
manufactur
reduc
elimin
use
substanc
anim
origin
manufactur
process
recent
sever
serum
proteinfre
cultur
media
becam
commerci
avail
although
use
defin
media
still
expens
largescal
product
ad
vector
requir
use
type
cultur
media
facilit
downstream
process
time
decreas
overal
process
cost
product
method
differ
accord
cell
type
use
adher
versu
suspens
cell
cultur
manufactur
purpos
suspens
adapt
cell
line
conveni
product
larg
scale
differ
oper
mode
develop
ad
product
figur
batch
mode
provid
easiest
way
proceed
extra
feed
requir
risk
contamin
lower
given
simplic
oper
ii
fedbatch
mode
easi
oper
readili
scalabl
employ
extend
cultur
lifetim
supplement
limit
nutrient
reduc
accumul
toxic
metabolit
iii
perfus
mode
consist
cell
retent
rel
high
concentr
insid
bioreactor
fresh
nutrient
suppli
metabolit
remov
take
place
see
kamen
review
methodolog
product
concentr
ad
vector
low
cost
mandatori
market
need
ad
increas
although
ad
advantag
produc
high
titer
pfuml
obtain
good
immun
respons
larg
proport
treat
anim
particularli
mucos
vaccin
larg
dose
thu
cultur
volum
requir
process
develop
aim
higher
yield
product
clearli
necessari
improv
volumetr
product
achiev
increas
cell
densiti
cell
infect
without
lower
specif
yield
product
howev
product
ad
vector
maintain
high
specif
yield
batch
oper
limit
cell
densiti
rang
cellsml
sever
approach
made
order
overcom
socal
cell
densiti
effect
garnier
et
demonstr
medium
replac
infect
addit
glucos
h
postinfect
hpi
togeth
period
ph
adjust
allow
sustain
maximum
specif
product
cellsml
wherea
nadeau
et
improv
strategi
also
ad
essenti
amino
acid
hpi
therebi
stabil
volumetr
product
cell
densiti
cellsml
result
hint
exist
substrat
limit
andor
byproduct
inhibit
high
cell
densiti
product
scale
medium
exchang
increas
cost
final
product
even
critic
use
veterinari
field
perfus
mode
oper
attempt
mean
control
cultur
environ
remov
toxic
byproduct
nevertheless
cellspecif
product
could
maintain
infect
cell
densiti
cellsml
use
high
perfus
rate
two
reactor
volum
per
day
day
postinfect
costli
laboratori
understand
kinet
metabol
infect
typic
cell
concentr
infect
alreadi
doubl
improv
seem
possibl
use
simpl
nonexpens
fedbatch
mode
import
infect
kinet
ad
product
signific
variabl
multipl
infect
moi
harvest
time
process
optim
also
mandatori
increas
product
yield
avoid
rapid
deplet
costli
certifi
master
viru
bank
well
ensur
infect
kinet
reproduc
differ
product
scale
moreov
use
low
moi
larg
scale
would
preferenti
sinc
intermedi
step
viru
inoculum
product
would
avoid
final
veterinari
product
purifi
minim
number
step
unit
oper
employ
simpl
nonexpens
tradit
laboratori
purif
rad
achiev
use
two
round
cesium
chlorid
cscl
densiti
gradient
ultracentrifug
howev
cscl
densiti
gradient
method
scaleabl
despit
fact
chromatograph
purif
expens
method
ion
exchang
hydrophob
interact
metal
chelat
sizeexclus
chromatographi
evalu
captur
purif
kamen
develop
complex
expens
method
gene
therapi
applic
consist
harvest
infect
cell
continu
centrifug
ii
cell
lysi
osmot
shock
iii
dnase
treatment
centrifugalcondit
iv
filtrat
v
anionexhang
chromatographi
vi
ultrafiltrationconcentr
vii
size
exclus
chromatographi
protocol
allow
largescal
purif
ad
vector
puriti
compar
cscl
gradient
method
howev
dramat
increas
final
product
price
well
beyond
reach
veterinari
util
introgen
develop
method
consist
singl
ion
chromatographi
run
concentrationdiafiltr
nucleas
treatment
total
recoveri
viru
product
laboratori
protocol
purifi
bulk
harvest
directli
bioreactor
lysi
without
concentr
step
use
ion
exchang
chromatograph
step
ultrafiltr
final
polish
step
gel
filtrat
progress
promis
preliminari
result
improv
access
veterinari
marketplac
hurdl
still
need
overcom
efficaci
safeti
eas
deliveri
cost
factor
depend
emea
committe
veterinari
medic
product
cvmp
regul
vaccin
develop
european
union
eu
meanwhil
unit
state
depart
agricultur
usda
anim
plant
health
inspect
servic
aphi
regul
develop
anim
vaccin
unit
state
us
unfortun
govern
regul
often
becom
extrem
cautiou
confront
new
technolog
alway
follow
strictli
sciencebas
assess
approach
criteria
regul
product
regulatori
issu
govern
use
ad
vaccin
farm
veterinari
clinic
yet
well
defin
although
guidelin
live
recombin
vector
vaccin
veterinari
use
avail
eu
rule
govern
medicin
product
ue
code
us
feder
regul
titl
cfr
main
regulatori
text
anim
veterinari
vaccin
product
drawback
use
ad
vector
veterinari
vaccin
rare
possibl
emerg
vector
due
rare
eventu
minut
homolog
recombin
event
viral
permiss
mammalian
host
cell
genom
viru
restor
gene
viral
genom
rca
reduc
elimin
problem
rca
human
cell
line
made
transform
primari
human
embryon
retinoblast
limit
homolog
viral
sequenc
expect
reduc
elimin
emerg
rca
viru
amplif
mani
virus
use
viral
vector
deliveri
foreign
antigen
see
yokoyama
et
review
develop
recombin
vaccin
may
valu
veterinari
field
especi
attenu
target
pathogen
possibl
immun
one
pathogen
must
rais
time
satisfactori
quantiti
target
pathogen
live
vaccin
produc
easili
safe
hand
practic
use
might
still
potenti
problem
must
overcom
exampl
safeti
issu
revers
virul
recombin
fieldtyp
virus
spread
environ
genet
stabil
select
good
viral
vector
recombin
viral
vaccin
determin
host
rang
vector
safeti
consider
replic
properti
stabil
amount
foreign
dna
insert
place
primari
immun
reaction
induc
antigen
express
vector
excit
advanc
biotechnolog
enabl
develop
new
vaccin
enorm
possibl
consid
unthink
newer
vaccin
approach
benefit
improv
basic
understand
immunolog
antigen
present
factor
import
sustain
memori
immun
respons
continu
improv
understand
natur
protect
immun
variou
infecti
diseas
allow
ration
design
vaccin
immun
strategi
gener
protect
immun
respons
infecti
diseas
vaccin
yet
exist
